TY - JOUR
T1 - Pancreatic Cancer’s PD1-Roadblock
T2 - When T-Cell Reinvigoration Is Not Enough
AU - Lander, Varintra E.
AU - DeNardo, David G.
N1 - Publisher Copyright:
©2023 American Association for Cancer Research.
PY - 2024/2/1
Y1 - 2024/2/1
N2 - PD1-blockade combinations in pancreatic ductal adenocarcinoma have been poorly effective, and the underlying reasons for this are unknown. A recent study revealed that chemoradiation plus PD1-blockade reinvigorates tumor-specific T cells; however, this T-cell activation is accompanied with exaggerated NFkB signaling, which may limit productive tumor-controlling immunity.
AB - PD1-blockade combinations in pancreatic ductal adenocarcinoma have been poorly effective, and the underlying reasons for this are unknown. A recent study revealed that chemoradiation plus PD1-blockade reinvigorates tumor-specific T cells; however, this T-cell activation is accompanied with exaggerated NFkB signaling, which may limit productive tumor-controlling immunity.
UR - http://www.scopus.com/inward/record.url?scp=85184150835&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-23-2991
DO - 10.1158/1078-0432.CCR-23-2991
M3 - Article
C2 - 38038687
AN - SCOPUS:85184150835
SN - 1078-0432
VL - 30
SP - 474
EP - 476
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 3
ER -